Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Apellis Pharmaceuticals (NASDAQ:APLS) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 a.m. PT. The company said a live webcast of the presentation will be posted on the Events and Presentations page in its Investors and Media section. A replay will be available for approximately 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, APLS declined 3.83%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: IMVT +1.29%, PTGX +0.74%, TLX +0.66%, while SRRK -2.71% and KYMR -5.93%, suggesting stock-specific factors for APLS.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Phase 3 results | Positive | +2.9% | Positive Phase 3 VALIANT results for EMPAVELI in C3G and IC-MPGN. |
| Nov 25 | Investor conferences | Neutral | +4.3% | Participation in Citi and Evercore healthcare investor conferences with webcasts. |
| Nov 12 | Clinical data update | Positive | +2.6% | Five-year GALE data showing SYFOVRE delayed GA progression by ~1.5 years. |
| Nov 05 | Investor conference | Neutral | -2.5% | Announcement of a Stifel healthcare conference presentation and webcast replay. |
| Oct 30 | Earnings report | Positive | -31.0% | Q3 2025 results with $458.6M revenue and strong SYFOVRE/EMPAVELI performance. |
Recent news often saw positive reactions to clinical and data updates, but a strong selloff followed seemingly strong Q3 2025 financials, indicating occasional negative reactions even on favorable fundamentals.
Over the last few months, Apellis reported several milestones. On Oct 30, 2025, Q3 results with total revenue of $458.6M and strong SYFOVRE/EMPAVELI sales led to a -31.01% move. Subsequent conference participation in November saw modest positive and negative reactions. Positive GALE data on SYFOVRE and Phase 3 VALIANT results for EMPAVELI in November and December were followed by gains of 2.61% and 2.86%. Today’s conference announcement fits the pattern of ongoing investor outreach alongside recent clinical and financial developments.
Market Pulse Summary
This announcement highlights Apellis’ upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with a webcast and a 90-day replay. It follows a series of significant updates, including strong Q3 2025 revenue of $458.6M and positive data for EMPAVELI and SYFOVRE. Historical reactions to conferences have been mixed, while clinical data often coincided with gains. Observers may focus on any incremental detail shared at the conference relative to these recent milestones.
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 11:15 a.m. PT.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.
Investor Contact:
Eva Stroynowski
ir@apellis.com
617.938.6229
FAQ
When is Apellis Pharmaceuticals (APLS) presenting at the J.P. Morgan Healthcare Conference?
Where can investors watch the Apellis (APLS) live webcast for the January 12, 2026 presentation?
How long will the replay of the Apellis (APLS) J.P. Morgan presentation be available?
What time zone is the Apellis (APLS) presentation time listed in for January 12, 2026?
Will Apellis (APLS) provide materials or slides with the January 12, 2026 webcast?
How can I find the Apellis (APLS) webcast after the J.P. Morgan presentation ends?
